Biostate AI and Weill Cornell Medicine are collaborating to develop AI models for personalized acute myeloid leukemia (AML) care. The partnership will utilize Biostate AI's RNA sequencing t…
Biostate AI and Weill Cornell Medicine are collaborating to develop AI models for personalized acute myeloid leukemia (AML) care. The partnership will utilize Biostate AI's RNA sequencing technology to analyze patient samples from Weill Cornell's biorepository. The goal is to create an AI model capable of AML subtype stratification, disease prognosis, and therapy selection.
By analyzing RNA expression, the AI aims to provide more accurate and personalized treatment decisions, potentially improving patient outcomes. The initial phase involves developing a prototype using retrospective samples, with plans to expand the study to a larger dataset for definitive model creation.
This collaboration reflects a commitment to translating academic research into practical applications for precision medicine.